Rheumatology and Rheumatoid Arthritis in the Twenty-First Century

Abstract

Rheumatoid arthritis (RA) has historically been a disabling and life-threatening disease. Features include joint pain, stiffness and swelling, joint damage, fatigue, loss of function, and loss of employment. Recent advances in treatment, particularly the use of conventional disease-modifying therapies earlier and in combination, and the advent of biological therapies, ensures that modern rheumatologists expect to help patient attain remission, with advantages of early presentation and effective therapies used in a “treatment to target” strategy. Adherence to UK National Institute for Health and Clinical Excellence guidance for RA, including early identification of disease, early and aggressive use of disease-modifying antirheumatic therapies, in combination or with biological agents, allows for much better disease control and perhaps remission. Delays to diagnosis will therefore become increasingly important, and the necessity for accurate diagnosis becomes crucial. The strategy of tight disease control may be more important than the contribution of individual drugs, even biological agents. Future prospects include the use of better outcome measures to define remission, better prediction of outcome, and thus better targeting of therapies. There is an urgent need for better individualized prognostic predictors. We must not forget the management of patients with pain owing to damage from advanced disease. Rheumatologists and radiologists must work together to appreciate the opportunities for patients from a greater understanding of disease measurement.

Keywords

rheumatoid arthritis - inflammatory arthritis - remission - prognostic factors - treatment to target

• References

• 1 A better life for people with rheumatoid arthritis. National Rheumatoid Arthritis Society Web site. Available at: http://www.nras.org.uk/
• 2 Providing answers today and tomorrow. Arthritis UK Web site. Available at: http://www.arthritisresearchuk.org/
• 3 Pohjankoski H, Latva K, Kautiainen H , et al. First-year purchases of disease-modifying drugs of incident patients with chronic juvenile arthritis in Finland. Clin Exp Rheumatol 2011; 29 (5) 878-881
• 4 Kvien TK. Epidemiology of disability in rheumatoid arthritis. Rheumatology (Oxford) 2002; 41 (2) 121-123
• 5 Grange M, Henderson C. Leg ulceration in rheumatoid arthritis. Nurs Times 2001; 97 (24) 63
• 6 Pratt AG, Isaacs JD, Mattey DL. Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23 (1) 37-48
• 7 Burmester GR. RA in 2011: Advances in diagnosis, treatment and definition of remission. Nat Rev Rheumatol 2012; 8 (2) 65-66
• 8 Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all?. Nat Rev Immunol 2010; 10 (8) 605-611
• 9 Postlethwaite AE. Can we induce tolerance in rheumatoid arthritis?. Curr Rheumatol Rep 2001; 3 (1) 64-69
• 10 Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol 2010; 29 (2) 156-183
• 11 Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther 2012; 91 (4) 607-620
• 12 Gravallese EM, Walsh NC. Rheumatoid arthritis: repair of erosion in RA—shifting the balance to formation. Nat Rev Rheumatol 2011; 7 (11) 626-628
• 13 Hamilton J, McInnes IB, Thomson EA , et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis 2001; 60 (6) 566-572
• 14 Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J Rheumatol 2002; 29 (8) 1639-1645
• 15 Pincus T, Sokka T. How can the risk of long-term consequences of rheumatoid arthritis be reduced?. Best Pract Res Clin Rheumatol 2001; 15 (1) 139-170
• 16 Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60 (10) 924-927
• 17 Deighton C, Scott DL. Treating inflammatory arthritis early. BMJ 2010; 341: c7384
• 18 Atzeni F, Sarzi-Puttini P. Rheumatoid arthritis: Why wait? Explaining delays in seeking therapy for early arthritis. Nat Rev Rheumatol 2012; 8 (4) 190-191
• 19 Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011; 25 (4) 549-567
• 20 Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011; 13 (Suppl. 01) S3
• 21 National Institute for Health and Clinical Excellence. NICE Clinical Guideline No. 79: Rheumatoid Arthritis. National Clinical Guideline for Management and Treatment of Rheumatoid Arthritis in Adults. London, UK: Royal College of Physicians: National Collaborating Centre for Chronic Conditions; 2009
• 22 Grigor C, Capell H, Stirling A , et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364 (9430) 263-269
• 23 Haraoui B, Smolen JS, Aletaha D , et al; Treat to Target Taskforce. Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Ann Rheum Dis 2011; 70 (11) 1999-2002
• 24 Haraoui B, Pope J. Treatment of early rheumatoid arthritis: concepts in management. Semin Arthritis Rheum 2011; 40 (5) 371-388
• 25 Drosos AA, Voulgari PV. Long-term efficacy and toxicity of a combination therapy in rheumatoid arthritis patients. Clin Exp Rheumatol 2001; 19 (1) 111
• 26 Hakala M, Risteli J, Aman S , et al; Fin-Raco Trial Group. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression. Scand J Rheumatol 2008; 37 (2) 90-93
• 27 Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002; 41 (8) 892-898
• 28 Gossec L, Dougados M. Combination therapy in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (5) (Suppl. 31) S174-S178
• 29 Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X. EMECAR Study Group. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 2003; 30 (4) 697-704
• 30 Furst DE, Pangan AL, Harrold LR , et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken) 2011; 63 (6) 856-864
• 31 Horton SC, Walsh CA, Emery P. Established rheumatoid arthritis: rationale for best practice: physicians' perspective of how to realise tight control in clinical practice. Best Pract Res Clin Rheumatol 2011; 25 (4) 509-521
• 32 Gülfe A, Aletaha D, Saxne T, Geborek P. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. BMC Musculoskelet Disord 2009; 10: 41
• 33 Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des 2011; 17 (29) 3141-3154
• 34 Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001; 134 (8) 695-706
• 35 van der Heijde D, Klareskog L, Rodriguez-Valverde V , et al; TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54 (4) 1063-1074
• 36 Hetland ML, Stengaard-Pedersen K, Junker P , et al; CIMESTRA study group. Radiographic progression and remission rates in early rheumatoid arthritis—MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010; 69 (10) 1789-1795
• 37 Hetland ML, Stengaard-Pedersen K, Junker P , et al; CIMESTRA Study Group. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006; 54 (5) 1401-1409
• 38 Goekoop YP, Allaart CF, Breedveld FC, Dijkmans BA. Combination therapy in rheumatoid arthritis. Curr Opin Rheumatol 2001; 13 (3) 177-183
• 39 van Vollenhoven RF, Geborek P, Forslind K , et al; Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2.  year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012; 379 (9827) 1712-1720
• 40 Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF , et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2008; 58 (2, Suppl) S126-S135
• 41 Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF , et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis 2007; 66 (9) 1227-1232
• 42 Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF , et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146 (6) 406-415
• 43 Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF , et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52 (11) 3381-3390
• 44 Rezaei H, Saevarsdottir S, Forslind K , et al. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 2012; 71 (2) 186-191
• 45 Kremer JM, Russell AS, Emery P , et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011; 70 (10) 1826-1830
• 46 Resman-Targoff BH, Cicero MP. Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am J Manag Care 2010; 16 (9, Suppl) S249-S258
• 47 Griffin AJ, Erkeller-Yuksel F. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) 2004; 43 (5) 678;- author reply 678–679
• 48 Hjardem E, Hetland ML, Østergaard M, Krogh NS, Kvien TK. Danish Database for Biological Therapies in Rheumatology Study Group. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis 2005; 64 (8) 1220-1223
• 49 Isaacs JD. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Expert Opin Biol Ther 2009; 9 (12) 1463-1475
• 50 Geyer M, Müller-Ladner U. Rationale of using different biological therapies in rheumatoid arthritis. Arthritis Res Ther 2010; 12 (4) 214
• 51 Finckh A, Ciurea A, Brulhart L , et al; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007; 56 (5) 1417-1423
• 52 Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40 (2) 205-211
• 53 Isaacs JD, Waldmann H. Regaining self-control—regulation and immunotherapy. Br J Rheumatol 1998; 37 (9) 926-929
• 54 Emery P, Buch MH. Towards an optimum strategy in rheumatoid arthritis. Lancet 2012; 379 (9827) 1682-1684
• 55 O'Dell JR. How is it best to treat early rheumatoid arthritis patients?. Best Pract Res Clin Rheumatol 2001; 15 (1) 125-137
• 56 Wolfe F, Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology (Oxford) 2005; 44 (Suppl. 04) iv18-iv22
• 57 Momohara S, Inoue E, Ikari K , et al. Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. Mod Rheumatol 2012; 22 (2) 209-215
• 58 González-Alvaro I, Descalzo MA, Carmona L. Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide Study Group. Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort. Arthritis Res Ther 2008; 10 (6) R138
• 59 Cimmino MA, Masocco M, Torre M. Hospital admission for rheumatoid arthritis dwindled in Italy between 2001 and 2008. Rheumatology (Oxford) 2011; 50 (11) 2140-2141
• 60 Dafydd M, Whitaker IS, Murison MS, Boyce DE. Change in operative workload for rheumatoid disease of the hand: 1,109 procedures over 13 years. J Plast Reconstr Aesthet Surg 2012; 65 (6) 800-803
• 61 Pap G, Shigeyama Y. Have the new drugs relieved the burden of the orthopedic surgeon?. Curr Opin Rheumatol 2001; 13 (3) 214-218
• 62 da Silva E, Doran MF, Crowson CS, O'Fallon WM, Matteson EL. Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment. Arthritis Rheum 2003; 49 (2) 216-220
• 63 Immonen K, Finne P, Grönhagen-Riska C , et al. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases—data from nationwide registries in Finland. Amyloid 2011; 18 (1) 25-28
• 64 Myasoedova E, Davis III JM, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010; 12 (5) 379-385
• 65 Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64 (11) 1595-1601
• 66 Greenwood MC, Doyle DV, Ensor M. Does the Stanford Health Assessment Questionnaire have potential as a monitoring tool for subjects with rheumatoid arthritis?. Ann Rheum Dis 2001; 60 (4) 344-348
• 67 Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64 (9) 1294-1298
• 68 Fransen J, Uebelhart D, Stucki G, Langenegger T, Seitz M, Michel BA. The ICIDH-2 as a framework for the assessment of functioning and disability in rheumatoid arthritis. Ann Rheum Dis 2002; 61 (3) 225-231
• 69 Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 (5) (Suppl. 39) S93-S99
• 70 Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006; 24 (6) (Suppl. 43) S-29-S-32
• 71 Schipper LG, Vermeer M, Kuper HH , et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 2012; 71 (6) 845-850
• 72 van Eijk IC, Nielen MM, van der Horst-Bruinsma I , et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford) 2012; 51 (4) 686-694
• 73 Boers M. The COBRA trial 20 years later. Clin Exp Rheumatol 2011; 29 (5) (Suppl. 68) S46-S51
• 74 Jayakumar K, Norton S, Dixey J , et al; Early Rheumatoid Arthritis Study (ERAS). Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford) 2012; 51 (1) 169-175
• 75 Yazici Y, Moniz Reed D, Klem C, Rosenblatt L, Wu G, Kremer JM. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Clin Exp Rheumatol 2011; 29 (3) 494-499
• 76 Jacobsson LT, Hetland ML. New remission criteria for RA: 'modern times' in rheumatology—not a silent film, rather a 3D movie. Ann Rheum Dis 2011; 70 (3) 401-403
• 77 Bykerk VP. Rheumatoid arthritis: 2011 remission criteria are a new benchmark for RA therapy. Nat Rev Rheumatol 2011; 7 (6) 317-318
• 78 Iikuni N, Inoue E, Tanaka E , et al. Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47 (4) 519-521
• 79 Cohen G, Gossec L, Dougados M , et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007; 66 (3) 358-363
• 80 Capell HA, Madhok R, Hunter JA , et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004; 63 (7) 797-803
• 81 Hammer HB, Sveinsson M, Kongtorp AK, Kvien TK. A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment. Ann Rheum Dis 2010; 69 (7) 1349-1351
• 82 Dejaco C, Duftner C, Wipfler-Freissmuth E, Weiss H, Graninger WB, Schirmer M. Similar performance of DAS-28, CDAI, and SDAI in rheumatoid arthritis patients with and without sonographic signs of active inflammation in routine clinical practice. Scand J Rheumatol 2011; 40 (3) 234-236
• 83 Bley TA, Ostendorf B, Scherer A, Kellner H, Schmidt WA. Magnetic resonance angiography in rheumatology. [in German]. Z Rheumatol 2012; 71 (5) 430-435
• 84 Schirmer M, Duftner C, Schmidt WA, Dejaco C. Ultrasonography in inflammatory rheumatic disease: an overview. Nat Rev Rheumatol 2011; 7 (8) 479-488
• 85 Bruyn GA, Schmidt WA. How to perform ultrasound-guided injections. Best Pract Res Clin Rheumatol 2009; 23 (2) 269-279
• 86 Ohrndorf S, Fischer IU, Kellner H , et al. Reliability of the novel 7-joint ultrasound score: results from an inter- and intraobserver study performed by rheumatologists. Arthritis Care Res (Hoboken) 2012; 64 (8) 1238-1243
• 87 de Thurah A, Nørgaard M, Johansen M, Stengaard-Pedersen K. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital. Scand J Rheumatol 2010; 39 (1) 19-25
• 88 Stack RJ, Shaw K, Mallen C, Herron-Marx S, Horne R, Raza K. Delays in help seeking at the onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative literature. Ann Rheum Dis 2012; 71 (4) 493-497
• 89 Wise EM, Isaacs JD. Management of rheumatoid arthritis in primary care—an educational need?. Rheumatology (Oxford) 2005; 44 (11) 1337-1338
• 90 Raza K, Stack R, Kumar K , et al. Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis 2011; 70 (10) 1822-1825
• 91 Nell-Duxneuner V, Rezende LS, Stamm TA, Duer M, Smolen JS, Machold KP. Attending and non-attending patients in a real-life setting of an early arthritis clinic: why do people leave clinics and where do they go?. Clin Exp Rheumatol 2012; 30 (2) 184-190
• 92 Daul P, Grisanti J. Monitoring response to therapy in rheumatoid arthritis—perspectives from the clinic. Bull NYU Hosp Jt Dis 2009; 67 (2) 236-242
• 93 van Tuyl LH, Smolen JS, Wells GA, Scholte-Voshaar M, Hoogland W, Boers M. Patient perspective on remission in rheumatoid arthritis. J Rheumatol 2011; 38 (8) 1735-1738
• 94 Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011; 70 (1) 4-7
• 95 Graell E, Vazquez I, Larrosa M , et al. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up. Clin Exp Rheumatol 2009; 27 (2) 284-291
• 96 Curtis JR, Yang S, Chen L , et al. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis 2012; 71 (2) 206-212
• 97 Pratt AG, Swan DC, Richardson S , et al. A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. Ann Rheum Dis 2012; 71 (8) 1374-1381
• 98 Forslind K, Hafström I, Ahlmén M, Svensson B. BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis?. Ann Rheum Dis 2007; 66 (1) 46-52
• 99 Plant D, Bowes J, Potter C , et al; Wellcome Trust Case Control Consortium ;British Society for Rheumatology Biologics Register. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011; 63 (3) 645-653
• 100 Huber LC, Pap T, Müller-Ladner U, Gay RE, Gay S. Gene targeting: roadmap to future therapies. Curr Rheumatol Rep 2004; 6 (5) 323-325
• 101 Fonseca JE, Cavaleiro J, Teles J , et al. Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter. Arthritis Res Ther 2007; 9 (2) R37
• 102 Gossec L, Dougados M, Goupille P , et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004; 63 (6) 675-680
• 103 Isaacs JD, Cohen SB, Emery P , et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2012; ; June 11 ( Epub ahead of print)
• 104 Houseman M, Potter C, Marshall N , et al. Baseline serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 2012; 14 (1) R30
• 105 D'Arcy CA, Willkens RF. Use of prognostic markets to guide biologic therapies for rheumatoid arthritis. J Rheumatol 2002; 29 (12) 2662;- author reply 2662–2663
• 106 Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 9 (4) 619-632
• 107 Goekoop-Ruiterman YP, Huizinga TW. Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA?. Nat Rev Rheumatol 2010; 6 (2) 68-70
• 108 Chatzidionysiou K, van Vollenhoven RF. When to initiate and discontinue biologic treatments for rheumatoid arthritis?. J Intern Med 2011; 269 (6) 614-625
• 109 D'Arcy Y. How to treat arthritis pain. Nursing 2002; 32 (7) 30-31
• 110 Al MJ, Maniadakis N, Grijseels EW, Janssen M. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Value Health 2008; 11 (4) 589-599
• 111 Ramiro S, Radner H, van der Heijde D , et al. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011; (10) CD008886
• 112 Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 2002; 47 (4) 391-397
• 113 Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 2001; 19 (7) 715-728
• 114 Hülsemann JL, Ruof J, Zeidler H, Mittendorf T. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study.'. Rheumatol Int 2006; 26 (8) 704-711
• 115 Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford) 2006; 45 (3) 325-331